



NDA 014602/S-059

SUPPLEMENT APPROVAL

Merck Sharp & Dohme Corp.
126 E. Lincoln Ave.
P.O. Box 2000, RY 32-461A
Rahway, NJ 07065-0900

Attention: Linda Birnbaum
Manager, Regulatory Affairs

Dear Ms. Birnbaum:

Please refer to your Supplemental New Drug Application (sNDA) dated August 4, 2014, received August 4, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Celestone Soluspan (betamethasone sodium phosphate and betamethasone acetate) Injectable Suspension, 6 mg/ml.

We acknowledge receipt of your amendment dated November 4, 2014.

This "Prior Approval" supplemental new drug application provides for revisions to the labeling, carton, and container label. They include revisions to the total drug content, the presentation of strength and concentration, and multiple revisions to the principle display panel. In addition, editorial changes were made throughout the package insert.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND IMMEDIATE CONTAINER LABELS

Submit final printed carton and immediate container labels that are identical to the: carton and immediate-container labels submitted on August 4, 2014, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 014602/S-059.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Sadaf Nabavian, Regulatory Project Manager, at (301) 796-2777.

Sincerely,

{See appended electronic signature page}

Badrul Chowdhury, MD, PhD
Director
Division of Pulmonary, Allergy, and
Rheumatology Products
Office of Drug Evaluation II
Center of Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

BADRUL A CHOWDHURY
02/04/2015